Literature DB >> 35094364

Employing Novel Porcine Models of Subcutaneous Pancreatic Cancer to Evaluate Oncological Therapies.

Alissa Hendricks-Wenger1,2,3, Margaret A Nagai-Singer2, Kyungjun Uh4, Eli Vlaisavljevich1,3, Kiho Lee4, Irving C Allen5,6.   

Abstract

Immunocompromised mice are commonly utilized to study pancreatic cancer and other malignancies. The ability to xenograft tumors in either subcutaneous or orthotopic locations provides a robust model to study diverse biological features of human malignancies. However, there is a dire need for large animal models that better recapitulate human anatomy in terms of size and physiology. These models will be critical for biomedical device development, surgical optimization, and drug discovery. Here, we describe the generation and application of immunocompromised pigs lacking RAG2 and IL2RG as a novel model for human xenograft studies. These SCID-like pigs closely resemble NOD scid gamma mice and are receptive to human tumor tissue, cell lines, and organoid xenografts. However, due to their immunocompromised nature, these immunocompromised animals require housing and maintenance under germfree conditions. In this protocol, we describe the use of these pigs in a subcutaneous tumor injection study with human PANC1 cells. The tumors demonstrate a steady, linear growth curve, reaching 1.0 cm within 30 days post injection. The model described here is focused on subcutaneous injections behind the ear. However, it is readily adaptable for other locations and additional human cell types.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Immunocompromised; Pancreatic; Porcine; Therapy; Ultrasound

Mesh:

Year:  2022        PMID: 35094364     DOI: 10.1007/978-1-0716-1811-0_47

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  26 in total

1.  Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.

Authors:  Robert C G Martin; Kelli McFarland; Susan Ellis; Vic Velanovich
Journal:  J Am Coll Surg       Date:  2012-06-21       Impact factor: 6.113

2.  Tissue ablation with irreversible electroporation.

Authors:  R V Davalos; I L M Mir; B Rubinsky
Journal:  Ann Biomed Eng       Date:  2005-02       Impact factor: 3.934

Review 3.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 4.  A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer.

Authors:  Imlimaong Aier; Rahul Semwal; Anju Sharma; Pritish Kumar Varadwaj
Journal:  Cancer Epidemiol       Date:  2018-12-08       Impact factor: 2.984

5.  Irreversible electroporation of the pancreas: definitive local therapy without systemic effects.

Authors:  Matthew Bower; Leslie Sherwood; Yan Li; Robert Martin
Journal:  J Surg Oncol       Date:  2011-02-28       Impact factor: 3.454

6.  Irreversible electroporation of locally advanced pancreatic head adenocarcinoma.

Authors:  Robert C G Martin
Journal:  J Gastrointest Surg       Date:  2013-08-09       Impact factor: 3.452

7.  Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.

Authors:  Robert C G Martin; David Kwon; Sricharan Chalikonda; Marty Sellers; Eric Kotz; Charles Scoggins; Kelly M McMasters; Kevin Watkins
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

8.  Preclinical in vivo evaluation of an extracorporeal HIFU device for ablation of pancreatic tumors.

Authors:  Joo Ha Hwang; Yak-Nam Wang; Cinderella Warren; Melissa P Upton; Frank Starr; Yufeng Zhou; Stuart B Mitchell
Journal:  Ultrasound Med Biol       Date:  2009-02-08       Impact factor: 2.998

9.  Targeted cellular ablation based on the morphology of malignant cells.

Authors:  Jill W Ivey; Eduardo L Latouche; Michael B Sano; John H Rossmeisl; Rafael V Davalos; Scott S Verbridge
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

10.  Characterization of Ablation Thresholds for 3D-Cultured Patient-Derived Glioma Stem Cells in Response to High-Frequency Irreversible Electroporation.

Authors:  J W Ivey; E M Wasson; N Alinezhadbalalami; A Kanitkar; W Debinski; Z Sheng; R V Davalos; S S Verbridge
Journal:  Research (Wash D C)       Date:  2019-04-28
View more
  1 in total

Review 1.  Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review.

Authors:  Alissa Hendricks-Wenger; Lauren Arnold; Jessica Gannon; Alex Simon; Neha Singh; Hannah Sheppard; Margaret A Nagai-Singer; Khan Mohammad Imran; Kiho Lee; Sherrie Clark-Deener; Christopher Byron; Michael R Edwards; Martha M Larson; John H Rossmeisl; Sheryl L Coutermarsh-Ott; Kristin Eden; Nikolaos Dervisis; Shawna Klahn; Joanne Tuohy; Irving Coy Allen; Eli Vlaisavljevich
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2021-12-31       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.